Myron McDonald
Family · Sylvester, GANPI 1275534190
Payments from drug & device makers
Across 98 payments — averaging $17.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$308
- Ironwood Pharmaceuticals, Inc$276
- Lilly USA, LLC$199
- Novo Nordisk$173
- Bayer$156
- AstraZeneca$140
- plus $429 from 13 others
What the payments were for
- Speaking & faculty fees$251%
- Food & beverage$1,65599%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 23 | $308 |
| Ironwood Pharmaceuticals, Inc | 16 | $276 |
| Lilly USA, LLC | 12 | $199 |
| Novo Nordisk | 9 | $173 |
| Bayer | 7 | $156 |
| AstraZeneca | 8 | $140 |
| AbbVie | 7 | $109 |
| Sunovion Pharmaceuticals Inc. | 3 | $67 |
| Amgen | 3 | $48 |
| Ardelyx, Inc. | 1 | $29 |
| Mckesson Medical-surgical, Inc. | 1 | $25 |
| Astellas Pharma US Inc | 1 | $25 |
| Antares Pharma, Inc. | 1 | $24 |
| Pfizer | 1 | $21 |
| Abbott | 1 | $20 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Corcept Therapeutics | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
How this compares
$1,680 in reported general payments places this provider in the 75th percentile of 6,258 family providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 69 | $76,979 |
| MounjaroTirzepatide | 52 | $49,868 |
| JanuviaSitagliptin Phosphate | 24 | $26,515 |
| EliquisApixaban | 26 | $25,365 |
| JardianceEmpagliflozin | 21 | $22,562 |
| FarxigaDapagliflozin Propanediol | 13 | $16,850 |
| LinzessLinaclotide | 22 | $10,962 |
| RybelsusSemaglutide | 11 | $10,348 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $3,791 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 39 | $1,741 |
| Gabapentin | 104 | $1,703 |
| Valsartan | 109 | $1,650 |
| Atorvastatin Calcium | 210 | $1,538 |
| Omeprazole | 109 | $1,536 |
| Tamsulosin Hcl | 56 | $1,125 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $173 | $87,32780 claims |
| Lilly USA, LLCMounjaro | $199 | $49,86852 claims |
| PfizerEliquis | $21 | $25,36526 claims |
| Boehringer IngelheimJardiance | $308 | $22,56221 claims |
| AstraZenecaFarxiga | $140 | $16,85013 claims |
| AbbVieLinzess | $109 | $10,96222 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,258 family providers in Georgia.
Other family in Sylvester
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
- Jessica FeehanCanton$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.